Dr. Cameron is an economist with over 25 years of experience consulting to attorneys and companies involved in commercial litigation, regulatory proceedings, and other complex matters. Her broad industry expertise includes pharmaceuticals, biologics, medical devices, health insurance, consumer products, motor vehicles, e-commerce, telecommunications, cryptocurrencies, and energy.

Dr. Cameron has worked on a wide array of valuation, false advertising, competition, and transfer pricing matters. She has analyzed damages, liability, and requests for injunctive relief. In patent disputes, Dr. Cameron has testified on both commercial success and damages. She has also testified in matters involving competition and investment incentives before the Federal Energy Regulatory Commission and state public utility commissions.

Prior to becoming a consultant, Dr. Cameron was a professor of economics at Carnegie Mellon University's Tepper School of Business, where she taught courses in microeconomic theory, regulation, and antitrust policy.

Education

- PhD in economics, Stanford University
- BSc in Business/Economics, Cornell University

Areas of Expertise

- Healthcare and Life Sciences
- Intellectual Property Damages and General Valuation
- False Advertising/Product Liability
- Competition and Regulation

Testifying Experience

- *The University of Sydney et al. v. ObjectiVision Pty Ltd*. (No. NSD 385 of 2014).
  - Report on Damages, December 2017.
  - Joint Report on Damages with Mr. Jeffrey Aroy, February 2018.
  - Joint Report on Damages with Mr. John Henry Eversgerd, February 2018.
- *Milwaukee Electric Tool Corporation et al. v. Chervon North America, Inc*. (Case No. 2-14-cv-01289-JPS).
  - Report on Commercial Success, July 2017.
- *Brigham and Women's Hospital, Inc. and Investors Bio-Tech, L.P. v. Perrigo Company and L. Perrigo Company* (Civ. No. 13-cv-1164).
  - Reports on Damages and Commercial Success, April 2016.
  - Deposition, May 2016.
  - Jury Trial, December 2016.
- Before the Federal Energy Regulatory Commission and the Regulatory Commission of Alaska, BP Pipelines (Alaska) Inc., Federal Energy Regulatory Commission (FERC) Docket No. IS09-348, RCA Docket P-08-9, October 2010.
- Before the Regulatory Commission of Alaska, In the Matter of the Application of Amerada Hess Pipeline Corporation and Phillips Transportation Alaska, Inc., for the Transfer of a 1.5% Interest in the Trans Alaska Pipeline System Docket No. P-02-10, November 2002.
- Before the Regulatory Commission of Alaska, In the Matter of the Application of BP Pipelines (Alaska), Inc. and Phillips Transportation Alaska, Inc. for the Transfer of a 3.0845% Interest in the Trans Alaska Pipeline System Docket No. P-01-08, May 2001 and July 2001.

Consulting Experience

Healthcare and Life Sciences

- On behalf of a leading biopharmaceutical manufacturer, prepared expert reports assessing lost profits and reasonable royalties owed by a rival company (which had allegedly infringed the client's patents to launch a closely competing drug). Explained how the activities of payers/PBMs can impact drug manufacturers' profits, both directly (through rebating requirements) and indirectly (through copay assistance programs and through time-limited full WAC buydown programs that cover the cost of units not paid for by insurance.) Quantified these impacts using data on the parties' experience in negotiating with individual formularies, as well as data from company financial records and strategic plans.
- On behalf of a leading biosimilar producer, worked on a patent infringement suit initiated by the producer of the reference biologic. Assessed the plaintiff's damages arising from the alleged infringement of six patents and rebutted damages analyses proffered by the plaintiff's economic experts. For each of the six patents, quantified the biosimilar producer's incremental benefits from licensing the patent and the plaintiffs' opportunity costs from granting the license. We also analyzed comparable agreements and apportionment criteria. The parties settled shortly after Brattle submitted its report.
- Worked on behalf of the University of Sydney, which had been accused of wrongfully terminating patent licenses granted to ObjectiVision, an Australian start-up producer of medical devices used to screen for glaucoma and other eye diseases. Prepared a report rebutting damages claims presented by two experts working on behalf of ObjectiVision, as well as joint reports with each expert. The report was used in successfully excluding the opposing experts' testimony.
- In a patent infringement suit against Perrigo, a leading manufacturer of store-brand over-the-counter (OTC) drugs, prepared an expert report on the reasonable royalty damages that would have been owed by the manufacturer, assuming that the patent was valid and infringed. Prepared an additional

expert report evaluating the commercial success of products that had allegedly infringed the patent at issue. Was deposed and later testified at trial.

- On behalf of Warner Chilcott, a major pharmaceutical company accused of "product hopping," supported multiple experts in their analysis of the competitive implications of this practice. Our reports and analyses showed that: (i) generic manufacturers can and do rely on a variety of mechanisms other than AB-rated substitution to sell their products and (ii) third-party payors can and do drive utilization from branded drugs towards cheaper therapeutic substitutes and that these shifts take place even when AB-rated generic substitutes are not available. Case won on summary judgment.
- In a False Claims Act case, prepared expert report explaining how an insurer's alleged misrepresentations allowed it to obtain Medicare Part D contracts and overcharge the government for services provided. Applied a claims adjudication model to hundreds of millions of plan records to establish the overcharge amount, which was calculated as the difference between government payments under actual coverage and represented coverage for the at-issue plans.
- Working on behalf of the Financial Oversight and Management Board for Puerto Rico, conducted analyses of several recently enacted laws related to health care in Puerto Rico. Our analyses focused on whether these laws could be expected to: (i) impact Puerto Rico's fiscal plans and budgets by reducing competition and (ii) affect the ability of the Puerto Rico's residents to access affordable healthcare.
- In an arbitration, worked on behalf of the respondent, a foreign producer of biosimilar drugs that had partnered with the claimant to pursue US business opportunities. The claimant sued the defendant for a portion of the alleged value of the venture (i.e., the sum of profits arising from three potential biosimilar drug candidates). Prepared two reports demonstrating that claimants' profit projections for the three drug candidates failed to account for the toughness of competition and the array of costs associated with biosimilar development and commercialization

- Worked on behalf of Quidel Corporation, a maker of immunoassays, which was involved in a contract dispute with Beckman Coulter Inc (Beckman), a producer of laboratory instruments. Under the terms of the contract, the parties collaborated on the production and sale of a test for congestive heart failure. While Beckman had originally agreed that it would not support or sell any competing tests, it later sought to have this exclusivity provision voided. Prepared expert report explaining that – in the absence of the exclusivity provision – Quidel would have had little incentive if any to invest in developing, marketing, and selling the test, which can only be used on Beckman machines.
- Worked on behalf of Horizon Pharmaceuticals in a proceeding before the Canadian Patented Medicine Prices Review Board (PMPRB) involving Horizon's orphan drug, PROCYSBI. Prepared expert report explaining: (i) the economic considerations associated with pricing orphan drugs; (ii) the price control methods typically applied to new drugs in Canada; and (iii) how novel price control methodologies that the PMPRB developed for PROCYSBI would impact Horizon's opportunity to earn a fair return on its investment in the drug in Canada.
- On behalf of Boston Scientific, prepared a report rebutting opposing expert's claims about the sources of competitive advantage in the company's cardiac rhythm management (CRM) and vascular intervention (VI) business segments.
- Worked on behalf of 3M, which had allegedly failed to disclose a regulatory pricing restriction when it sold off its pharmaceuticals division. Prepared testimony that quantified the damages resulting from this alleged non-disclosure. Using historical drug pricing data and publicly available policy documents, examined trends in the underlying regulatory environment and the impact of generic penetration – trends that the buyer should have been knowledgeable about prior to purchase. Also assessed the degree to which the information in the pricing contract was already encompassed in sales forecasts and other disclosures made during the acquisition process. All claims were dismissed in court following trial.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.